The Biotech Capital Compass
Biotechnology & ‘Fog of Valuation’ savant
| Platform |  | Pricing | Freemium | Publishes | Daily |
|---|---|---|---|---|---|
| Issues | 240 | Founded | 2 years ago | Last Issue | 7 days ago |
| Active | |||||
Read this Newsletter
hartajsingh1.substack.comLatest Issues
The Long Climb: Assembly Biosciences (ASMB) — What Comes After the Bridge?
The Gilead partnership helped Assembly rebuild. Now ABI-6250, its proprietary pipeline and capital allocation must show where that bridge ultimately leads.
Several weeks ago, we examined how Assembly Biosciences rebuilt itself following th...
Video Companion: Reading the Signals as Biotech Normalizes
Biotechnology is sending investors a complicated collection of signals.
M&A remains active. The IPO market is reopening selectively. Biotech specialist investors appear to be generating better returns. At the same time, Treasury yields hav...
Video Recap: Is Biotechnology Beginning to Feel Normal Again?
After two difficult years, biotechnology increasingly appears to be behaving more like a functioning capital market again—not uniformly strong or free from risk, but selective, differentiated, and increasingly focused on execution.
In this...
The Biotech Exchange: Moderna, INT and the Next Test for Personalized Cancer Therapy
This conversation was originally published by Katerina at Biotech Blueprint, and we are pleased to republish it here for Biotech Capital Compass readers.
Katerina and I approach biotechnology from somewhat different perspectives, which is...
The Expectations Game: Playing Biogen’s Hand
Biogen’s business is improving, but five approaching Phase 3 readouts test how investors should value opportunity before the cards are revealed.
Biogen’s operating picture has improved considerably since our May 2026 update. The Apellis ac...
Audience Metrics
Subscribers, engagement, traffic and sponsorship for The Biotech Capital Compass.
| Subscribers | Engagement | 71 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
Explore More
Authors
The writers behind this newsletter.
Biotech Capital Compass breaks down complex biotech stories into valuation, risk, and narrative frameworks investors can use. Written by Hartaj Singh, a biotech analyst focused on translating innovation into investment reality.
Frequently Asked Questions
How can I access the email archive for The Biotech Capital Compass?
You can find recent issues that have been published by The Biotech Capital Compass on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does The Biotech Capital Compass have?
To see how many people subscribe to The Biotech Capital Compass, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in The Biotech Capital Compass?
Newsletter advertising can be extremely effective when it's done right. Before you pitch The Biotech Capital Compass as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like The Biotech Capital Compass?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact The Biotech Capital Compass using the contact information provided and ask for a copy of their media kit.
How can I find newsletters related to The Biotech Capital Compass?
Scroll up to where it says Related Newsletters to see other publications like The Biotech Capital Compass. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact The Biotech Capital Compass?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.